2 results
Approved WMOPending
Primary Objectives:• Evaluate the safety and tolerability of sparsentan oral suspension (Population 1 and Population 2) and tablets (Population 3)• Assess changes in proteinuria after once-daily dosing of sparsentan oral suspension and tablets over…
Approved WMORecruiting
Primary Objective: To investigate the effects of LT4/LT3 combination therapy compared to LT4 monotherapy on tiredness in those patients with autoimmune hypothyroidism and persisting tiredness on LT4 monotherapy, after 1 year of treatment.In case it…